Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
52
resultados
Última actualización
01/05/2025 [07:32:00]
Resumen de: WO2024240079A1
The present invention relates to the technical field of medicines. Disclosed are a detection marker, a diagnostic marker, a use thereof, and a kit. In the present invention, PPP2R5C is used as a detection marker for the preclinical stage of Alzheimer's disease (AD) and as a diagnostic marker for mild cognitive impairment and AD; thus, the problems of detection defects and lack of effective blood biomarkers in lumbar puncture and PET-CT detection methods used in early diagnosis of AD are solved.
Resumen de: WO2025081242A1
The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.
Resumen de: US2025130246A1
The disclosure relates to methods of investigating protein aggregation reactions, in particular methods for detecting aggregates of a protein that are capable of seeding further protein aggregation. The methods allow not only understanding of aggregation reactions, but also provide means for detecting whether a sample from an individual comprises aggregate seeds.
Resumen de: AU2023351193A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Resumen de: AU2023294616A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.
Resumen de: US2025123296A1
A level of mouse Aβ1-40 and a level of mouse APP669-711 in a biological sample derived from an AD model mouse are measured by detection of markers including mouse Aβ1-40 and mouse APP669-711; an APP669-711/Aβ1-40 ratio which is a ratio of the level of mouse APP669-711 to the level of mouse Aβ1-40 is calculated; and when the ratio in the AD model mouse is higher than the same ratio in a reference mouse in which cerebral Aβ deposition is absent, it is judged that an amount of cerebral Aβ deposition in the AD model mouse is higher than an amount of cerebral Aβ deposition in the reference mouse.
Resumen de: US2025123297A1
Disclosed herein is a newly identified secreted nanoparticle that is morphologically and molecularly distinct from the recently described nanoparticle termed an exomere. The disclosed nanoparticle is referred to herein as a supermere. Both exomeres and supermeres are amembranous in contrast to membrane-enclosed extracellular vesicles (EVs). Supermeres are smaller and morphologically distinct from exomeres. These supermeres contain cargo with diagnostic and therapeutic applications.
Resumen de: US2025122570A1
Methods are provided for identifying Alzheimer's disease cells or subjects, based on the methylation status of multiple methylation markers in genomic DNA. Also provided are methods for identifying therapeutic agents for treating Alzheimer's disease by monitoring changes in the methylation status of multiple methylation markers.
Resumen de: WO2025080894A1
In one aspect, the present disclosure provides a method of detecting a presence or absence of a biomarker for a disease in the sample, wherein the biomarker comprises: a) a complex of physiologically active target macromolecules or a fragment or portion thereof and target macromolecules that are not physiologically active; b) a conformation of the physiologically active macromolecules or fragment thereof when the physiologically active target macromolecules or the fragment or portion thereof is a complex with a non- physiologically active target macromolecule; c) the conformation of physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; d) the conformation of non-physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; or e) a combination of a), b), c), d) and/or e).
Resumen de: AU2023294616A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.
Resumen de: AU2023356443A1
Provided is a protein marker Nell-1, which is present in a person's blood sample in an amount that is correlated with neurodegenerative disorders such as Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), and Parkinson's Disease (PD). Corresponding diagnostic and treatment methods for these neurodegenerative disorders as well as kits for diagnosing or treating the neurodegenerative disorders are also provided.
Resumen de: WO2025076222A1
Human tau protein phosphorylated at the amino acid, serine 413 (pS413 tau), can serve as a biomarker for tauopathies such as Alzheimer's disease. Detection and quantitation of pS413 tau in a biological sample such as cerebrospinal fluid can be useful in developing therapeutics for certain tauopathies. However, pS413 tau is present in biological samples at very low levels. Thus, the invention provides a highly sensitive assay for the detection and quantitation of pS413 tau in a biological sample comprising a series of steps as described herein.
Resumen de: US2025115952A1
In the field of aptamers, closed sequence solution space libraries for aptamer selection and related methods for selecting aptamers for binding to target molecules. Also, a method of treating a disease or disorder in a subject, including diagnosing, monitoring, or predicting a using at least one aptamer obtained by the closed sequence solution space libraries, and treating the diagnosed subject. Further a specific set of aptamers, which may be used for detection and/or quantification of a target molecule.
Resumen de: US2025116035A1
In the field of aptamers, closed sequence solution space libraries for aptamer selection. Also, methods for selecting aptamers for binding to target molecules in which biological samples derived from individuals that differ by phenotype are contacted with the library of aptamers and the aptamer oligonucleotides that bound to the target molecules are covered. Further, methods of treating a disorder or a disease of a subject in which the disorder or disease is diagnosed using the library of aptamers and the subject is treated.
Resumen de: US2023349925A1
The present invention addresses the problem of providing: a determination method that can determine, early and with ease, whether or not a disease caused by synaptic dysfunction or a disease accompanied by synaptic dysfunction has occurred, and the severity level of the disease; and a screening method for a therapeutic agent and a prophylactic agent for a disease caused by synaptic dysfunction or a disease accompanied by synaptic dysfunction. The present invention provides a determination method that can determine disease caused by synaptic dysfunction or a disease accompanied by synaptic dysfunction early and with ease and also can contribute to drug discovery research for these diseases, with a determination method for determining whether or not a disease caused by synaptic dysfunction or a disease accompanied by synaptic dysfunction has occurred, where drebrin A-related proteins (DARPs) serve as indices, and with a screening method for screening a therapeutic agent and prophylactic agent for a disease caused by synaptic dysfunction or a disease accompanied by synaptic dysfunction, where drebrin A-related proteins (DARPs) serve as indices.
Resumen de: MX2020011458A
The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
Resumen de: EP4535003A1
Provided is a method for analyzing a neurogranin-related peptide capable of suppressing variations in analysis results, and a method for preparing a biological sample containing a neurogranin-related peptide used therein. A method for preparing a sample solution containing a neurogranin-related peptide, the method includes mixing a biological sample containing a neurogranin-related peptide with an organic solvent having a relative polarity of 0.200 or more and 0.700 or less to prepare a sample solution having a final concentration of the organic solvent of 5.0 (v/v)% or more.
Resumen de: CN117589996A
The invention relates to a diagnostic use of highly toxic amyloid oligomers. Specifically, the present invention relates to the use of a novel highly toxic amyloid oligomer A beta o * 3F, specifically bound by a 3F antibody, in the cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and AD-derived MCI patients, as a target for the diagnosis of early and mid-advanced Alzheimer's disease (AD) and AD-derived mild cognitive impairment (MCI), the Abeta oligomers have the advantages that the Abeta oligomers are high-toxicity oligomers, the levels of the Abeta oligomers are remarkably different in CSF, blood and/or brain tissues of AD patients, MCI patients and healthy old people, and the Abeta oligomers are super-toxicity oligomers, are the most major toxic components in A beta oligomer mixtures, have strong pathogenic effects and play a key role in occurrence and development of AD.
Resumen de: WO2025068747A1
The present invention relates to the field of neurodegenerative diseases detection and diagnosis, in particular to a delivery system comprising bodipy markers, said delivery system consisting of a modified humanized ferritin from Archaeoglobus fulgidus (HumAfFt) and a bodipy fluorescent marker that selectively binds the TAU protein, compositions comprising said delivery system and methods ad uses thereof.
Resumen de: WO2025068791A1
The present invention relates to the field of neurodegenerative diseases detection and diagnosis, in particular to a delivery system comprising bodipy markers, said delivery system consisting of a modified humanized ferritin from Archaeoglobus fulgidus (HumAfFt) and a bodipy fluorescent marker that selectively binds the TAU protein, compositions comprising said delivery system and methods ad uses thereof.
Resumen de: AU2023329158A1
The invention relates to methods of detecting, diagnosing or monitoring an inflammatory condition of the central nervous system, in particular by detecting or measuring neutrophil extracellular traps, extracellular traps and/or cell free nucleosomes.
Resumen de: AU2023329330A1
Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Resumen de: US2025101491A1
Method for diagnosing Alzheimer's disease in an individual, comprising the steps of providing at least one serum sample derived from the individual, providing at least one preparation of phage clones expressing peptides that mimic conformational epitopes of the Aβ-42 peptide, reacting said at least one serum sample with said at least one preparation of phage clones expressing peptides that mimic conformational epitopes of Aβ-42, so that antibodies that may be present in said serum and are directed against the Aβ-42 peptide bind to the peptides expressed by phage clones of said preparation of phage clones, detecting, by real-time PCR technique, the quantity of phage clones of said preparation to which said antibodies have bound, and determining, based on the quantity of phage clones of said preparation to which said antibodies have bound, whether the individual from whom said serum sample was derived suffers from Alzheimer's disease.
Resumen de: US2025101018A1
Described herein are compounds of formula (I), and pharmaceutically acceptable salts, solvates, hydrates, isotopically labeled derivatives and radiolabeled derivative thereof, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for detecting and imaging Tau aggregates in the brain for detection of Alzheimer's disease (AD) in a subject.
Nº publicación: CO2025003552A2 27/03/2025
Solicitante:
WASHINGTON UNIV [US]
WASHINGTON UNIVERSITY
Resumen de: AU2023329330A1
Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
BOPI
Sede Electrónica
